Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 1/2006

01-01-2006 | Concise Article

Evaluation of a novel kit for the rapid detection of extended-spectrum beta-lactamases

Authors: R. Colodner, B. Reznik, V. Gal, H. Yamazaki, H. Hanaki, R. Kubo

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 1/2006

Login to get access

Abstract

Since a method of rapidly detecting extended-spectrum beta-lactamase (ESBL) production in gram-negative isolates from patients with severe infection is urgently required, the present study of a novel commercial kit was conducted. The Cica-Beta Test I (Kanto Chemical, Tokyo, Japan) is designed for the rapid detection of ESBL in gram-negative bacteria directly from isolated colonies in a 15-min protocol. In this study, a total of 304 strains of Klebsiella spp., Escherichia coli and Proteus mirabilis were tested using the novel kit and the phenotypic confirmatory disk test using cefotaxime and ceftazidime with and without clavulanate. The kit showed 95.5 and 98.1% sensitivity and specificity, respectively, as compared to the disk test, and thus proved to be an appropriate tool for the rapid detection of ESBL.
Literature
1.
go back to reference Bush K (1996) Is it important to identify extended spectrum beta-lactamase producing isolates? Eur J Clin Microb Infect Dis 15:361–364CrossRef Bush K (1996) Is it important to identify extended spectrum beta-lactamase producing isolates? Eur J Clin Microb Infect Dis 15:361–364CrossRef
2.
go back to reference Livermore DM (1995) Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557–584PubMed Livermore DM (1995) Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557–584PubMed
3.
go back to reference Gianneli D, Tzelepi E, Tzouvelekis LS, Mentis AF, Nikolopoulou C (1994) Dissemination of cephalosporin-resistant Serratia marcescens strains producing a plasmidic SHV type beta-lactamase in Greek hospitals. Eur J Clin Microbiol Infect Dis 13:764–767PubMedCrossRef Gianneli D, Tzelepi E, Tzouvelekis LS, Mentis AF, Nikolopoulou C (1994) Dissemination of cephalosporin-resistant Serratia marcescens strains producing a plasmidic SHV type beta-lactamase in Greek hospitals. Eur J Clin Microbiol Infect Dis 13:764–767PubMedCrossRef
4.
go back to reference Hall LMC, Livermore DM, Gur D, Akova M, Akalin HE (1993) OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 37:1637–1644PubMed Hall LMC, Livermore DM, Gur D, Akova M, Akalin HE (1993) OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 37:1637–1644PubMed
5.
go back to reference National Committee for Clinical Laboratory Standards (2004). Performance standards for antimicrobial susceptibility testing. Fourteenth informational supplement. Approved standard M100-S14. NCCLS, Wayne, PA National Committee for Clinical Laboratory Standards (2004). Performance standards for antimicrobial susceptibility testing. Fourteenth informational supplement. Approved standard M100-S14. NCCLS, Wayne, PA
6.
go back to reference Hanaki H, Kubo R, Nakano T, Kurihara M, Sunagawa K (2004) Characterization of HMRZ-86: a novel chromogenic cephalosporin for the detection of extended-spectrum beta-lactamases. J Antimicrob Chemother 53:888–889PubMedCrossRef Hanaki H, Kubo R, Nakano T, Kurihara M, Sunagawa K (2004) Characterization of HMRZ-86: a novel chromogenic cephalosporin for the detection of extended-spectrum beta-lactamases. J Antimicrob Chemother 53:888–889PubMedCrossRef
Metadata
Title
Evaluation of a novel kit for the rapid detection of extended-spectrum beta-lactamases
Authors
R. Colodner
B. Reznik
V. Gal
H. Yamazaki
H. Hanaki
R. Kubo
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 1/2006
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-005-0074-y

Other articles of this Issue 1/2006

European Journal of Clinical Microbiology & Infectious Diseases 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine